Abstract
Introduction
Many poorly immunogenic murine and human cancers are defective in the presentation of cytosolic antigens due to a diminished synthesis of proteins crucial to the endogenous pathway of antigen presentation (1) (2) (3) (4) (5) . The presentation of endogenous antigens at the cell surface depends on the ordered trafficking of MHC molecules and peptides between the cytosol and the endoplasmic reticulum (ER) (6) . Antigenic peptides derived from the specialized proteolysis of cytosolic proteins are actively translocated into the ER by the activity of the transporter associated with antigen processing (TAP) (7, 8) . These peptides then form stable complexes with MHC class I α chain and β 2 -microglobulin (β 2 M) which are translocated to the cell surface, where they can be recognized by T cells.
The assembly of MHC class I-peptide complexes is facilitated by several ER-resident molecular chaperones through binding to and protecting unassembled subunits from aggregation (9) . Cytosolic chaperones, which influence the localization, assembly and turnover of cellular proteins (10) , have been implicated in the augmentation of MHC class IIrestricted T cell responses (11, 12) , as well as in the priming of MHC class I-restricted CTL responses to tumor cells (13) (14) (15) . Here we report that the constitutive expression of the human cytosolic chaperone heat shock protein (Hsp) 72 in poorly immunogenic melanoma cells restores surface MHC class I expression and endogenous antigen presentation in vitro, and enhances the immunogenicity of these tumor cells in vivo. Expression of Hsp72 in the TAP-mutant cell line RMA-S did not complement the defect in MHC class I surface expression and endogenous antigen presentation exhibited by these cells. These results demonstrate a role for cytosolic chaperone activity in the MHC class I antigen presentation pathway and further support a role for cellular heat shock proteins in the modulation of tumor immunogenicity.
Methods

Plasmids
The pSRαneo.hsp72 plasmid was constructed by insertion of the 2600 bp BamHI fragment from pG1HSP (kindly provided by Dr William Welch), which contains the human inducible hsp72 cDNA (16) , into the vector pSRαneo (17) . Transcription of cloned genes in this vector is driven by the strong eukaryotic promoter SRα (18) .
Mice, cell lines and antibodies
Female C57BL/6 and BALB/c mice were obtained from Harlan Sprague-Dawley (Madison, WI) and used in experiments at 6-10 weeks of age. The B16 melanoma (H-2 b ) the P815 mastocytoma (H-2 d ) and the L929 (H-2 k ) fibroblastiod cell lines were provided by Dr Joel Haynes. The RMA-S lymphoma (H-2 b ) was provided by Dr Peter Cresswell and L929-D b was provided by Dr Daniel Muller. All cell lines were cultured in RPMI supplemented with 10% FBS (Intergen, Purchase, NY), 2 mM L-glutamine, 100 IU/ml of penicillin, 100 µg/ml streptomycin, 50 µg ciprofloxacin and 25 mM HEPES. The mAb C92 (StressGen, Victoria, BC, Canada) recognizes the human and mouse heat-inducible Hsp72 gene products, but not the constitutive Hsc73. mAb M1/42 (ATCC TIB126) (19) and MS/ 114 (ATCC TIB120) recognize monotypic determinants of the murine H-2 (MHC class I) and I-A (MHC class II) antigens respectively. Rabbit antiserum which recognizes unfolded MHC class I α chains (K b and D b ) (20) was kindly provided by Dr H. Ploegh. mAb B22.249 (kindly provided by Dr Alain Townsend) recognizes a conformation-dependent determinant of the α2 domain of peptide-bound D b (21) . The mAb AF6-88.5 (PharMingen, San Diego, CA) is specific for K b . The dilutions of M1/42, AF6-88.5 and B22.249 mAb used in this study represent a super-saturating concentration as determined by flow cytometric titration against the highly MHC class I-positive cell lines L929, P815 and EL4.
Generation of stable tumor cell transfectants which constitutively express Hsp72
Approximately 5 ϫ 10 6 tumor cells were transfected by electroporation with 10 µg of pSRαneo or pSRαneo.hsp72 DNA in serum-free RPMI. Transfectants were cultured in supplemented RPMI plus 0.8 mg/ml (active) G-418 (Geneticin; Life Technologies, Grand Island, NY), and the resultant G-418-resistant colonies were picked and maintained in the presence of 0.3 mg/ml G-418. Stable clones were then screened for the expression of Hsp72 by immunoblot and flow cytometric analysis.
SDS-PAGE and immunoblot protein analysis
Proteins from tumor cell lysates prepared in Laemmli buffer were resolved by SDS-PAGE and transferred to nitrocellulose membranes by semi-dry electrophoresis (22) . The membranes were incubated with the indicated dilution of either rabbit antiserum against unfolded MHC class I α chains or rabbit antiserum against actin (Sigma, St Louis, MO). Immunoreactive proteins were visualized by incubation of the membranes with peroxidase-conjugated, affinity-purified goat anti-rabbit serum (diluted 20,000-fold; Boehringer Mannheim, Indianapolis, IN), followed by the addition of a chemilumninescent substrate (Boehringer Mannheim). Band densities (in pixels/cm 2 ) were quantified from digitized blot images using NIH Image 1.60b7 image analysis software.
Flow cytometric analysis of surface and intracellular proteins Adherent tumor cell monolayers were harvested in PBS containing 1 mM EDTA, washed in supplemented RPMI and 2.5 ϫ 10 5 cells were incubated with the appropriate mAb (1 µg or 50 µl hybridoma supernatant) in a final volume of 100 µl for 30 min at 4°C. Cells were washed with cold PBS containing 2% calf serum and incubated with 1 µg FITCconjugated goat anti-rat or -mouse antibody (Boehringer Mannheim) for 30 min at 4°C. For intracellular staining, 2.5 ϫ 10 5 cells were fixed with 1% formaldehyde in PBS, and permeabilized in PBS containing 2% calf serum and 0.1% saponin. Permeabilized cells were incubated at room temperature for 2 h with primary antibody (2 µg or a 5000-fold dilution of ascites), followed by a 1 h incubation with FITCor phycoerythrin (PE)-conjugated goat anti-mouse antibody or FITC-conjugated avidin (Becton Dickinson, San Jose, CA). Fluorescence was measured using a Becton Dickinson FACScan flow cytometer.
Generation of CTL effector populations
Lymphocytic choriomeningitis virus (LCMV)-specific CTL were generated as described (23) . Briefly, C57BL/6 or BALB/c mice were injected i.p. with 2 ϫ 10 6 p.f.u. of the Armstrong 53b strain of LCMV. After 7 days, the mice were sacrificed, the spleens were harvested and the unfractionated splenocytes were used as effectors. LAK were generated from allogeneic splenocytes by culture in supplemented RPMI with the addition of 1000 U/ml recombinant human IL-2 (Biological Response Modifiers Program, Washington, DC) for 3-5 days.
CTL assay
Effectors were plated in 96-well plates at the indicated ratios with 51 Cr-labeled (100 µCi of Na 2 [ 51 Cr]O 4 /10 6 cells for 1 h; ICN Biomedicals, Costa Mesa, CA) target cells, incubated at 37°C for 5 h and the cell-free supernatants were harvested with glass fiber filter frames (Skatron Instruments, Sterling, VA). LCMV-infected targets were infected with the Armstrong 53b strain at a multiplicity of 1 p.f.u./cell, 2 days prior to the assay. 51 Cr emission was measured using a Minaxi AutoGamma 5000 counter (Packard, Downers Grove, IL) and percent specific lysis was calculated as described (24) .
In vivo immunization and tumor rejection assay B16 transfectants to be used as an immunogen were growth inhibited by treatment with mitomycin C (25 µg/ml for 3 h; Boehringer Mannheim), harvested in PBS containing 1 mM EDTA and washed in PBS. Mitomycin C-treated tumor cell suspensions were then γ-irradiated (5000 rad), washed in PBS and resuspended at 5 ϫ 10 6 cells/0.2 ml PBS. At days 0 and 10 of each experiment, C57BL/6 mice (four to five per group) were injected either i.p. or s.c. with 0.2 ml PBS, or with inactivated tumor cell suspensions (5 ϫ 10 6 cells) in 0.2 ml PBS. Immunized mice were then challenged on day 20 by s.c. injection of 2 ϫ 10 4 wild-type B16 tumor cells (viability Ͼ98%) suspended in 0.1 ml PBS. The 50% tumorigenic dose of the B16 melanoma cells used in these studies was determined to be~2 ϫ 10 3 cells. Doses of 5 ϫ 10 3 , 10 4 and 2 ϫ 10 4 cells lead to progressively growing tumors in 100% of naive mice challenged s.c. Incidence of the challenge tumor was assessed by palpation of the challenged flank and was scored as positive on the day that the established tumor reached 25 mm 2 as measured by tissue calipers. Mice were sacrificed before challenge tumors reached 500 mm 2 or if mice developed ascites from the immunizing tumor cell dose.
Results
Increased level of MHC class I surface antigens on Hsp72-expressing melanoma cells B16 is a highly malignant melanoma which arose spontaneously in a C57BL/6 (H-2 b ) mouse (25) . This tumor cell line is poorly immunogenic and expresses very little surface MHC class I antigen as detected by flow cytometry (26) . To investigate whether molecular chaperone activity can influence the capacity of this cell line to present endogenous antigens, we generated stable clones of B16 which constitutively express the human heat-inducible 72 kDa chaperone ( Fig. 1A and B) . Flow cytometric analysis using the monotypic mAb M1/42 revealed significant levels of stably folded MHC class I antigen on the surface of these Hsp72-expressing clones ( Fig. 2A) . This increase in surface MHC class I was not observed on corresponding clones which express only the control bacterial aminoglycoside phosphotransferase (neo) protein. Control-transfected clones exhibited MHC class I profiles similar to those of the parent B16 cell line (Fig. 2B ). This Hsp72-mediated effect is MHC class I specific, because the surface expression of another related membrane protein, MHC class II, is not affected by Hsp72 expression (not shown). The surface expression of both K b and D b gene products was shown to be up-regulated on B16 cells expressing Hsp72 (Fig. 2C and D) . Despite these differential surface levels, Hsp72-expressing cells and control cells contain comparable levels of total MHC class I α chain protein, as assessed by immunoblot analysis of whole cell extracts with an antiserum that recognizes free K b and D b α chains (20) (Fig. 2E) . Table 1 Enhanced presentation of endogenous antigens to MHC class I-restricted T cells
To address whether this Hsp72-mediated increase in the surface expression MHC class I molecules on B16 melanoma cells corresponds to an enhanced capacity of these cells to present endogenous antigens, Hsp72-expressing B16 clones infected with LCMV were used as targets for LCMV-specific, MHC class I-restricted CTL in vitro. LCMV infection of mice with the H-2 b haplotype induces a CTL response specific for an immunodominant epitope (GWTGSDGKTTWCSQ) derived from the viral GP gene product, as well as for several subdominant epitopes (27) . The efficacy of these H-2 brestricted CTL is largely dependent on the quantity of this peptide which is processed and presented in the context of the D b allele of MHC class I (28). We have found that LCMVinfected, Hsp72-expressing B16 cells are recognized and killed by LCMV-specific CTL to a greater degree than controltransfected B16 cells, and that this killing is MHC-restricted (Fig. 3) . Lysis of Hsp72-expressing B16 cells exceeded that of L929 (H-2 k ) cells transfected with D b , even though L929- Table 1 ). The possibility that the expression of Hsp72 merely made the cells more susceptible to lysis by cytotoxic effector mechanisms is unlikely, because non-specific, LAK cells lysed the Hsp72-expressing clones to the same degree as control clones (Fig. 4) .
Effect of TAP mutation on the enhancement of MHC class I surface expression and endogenous antigen presentation by Hsp72
In order to further understand the mechanism by which Hsp72 influences MHC class I surface expression and endogenous antigen presentation, we employed the TAP-mutant cell line RMA-S (29), which is deficient in the supply of cytosolic peptides into the ER. This cell line lacks functional surface MHC class I expression and endogenous antigen presentation due to an inability to assemble MHC-peptide complexes (30) . Stable transfectants of RMA-S which constitutively express Hsp72 at levels comparable to those exhibited by Hsp72-transfected B16 clones (Fig. 5) did not exhibit an increase in the amount of functionally conformed MHC class I molecules on the cell surface compared to control transfectants (Table  2) . RMA-S cells expressing Hsp72 were also unable to present endogenous antigens to MHC class I-restricted T cells (Fig. 6 ).
Enhanced immunogenicity of chaperone-expressing tumor cells in vivo
Wild-type B16 melanoma cells are unable to elicit a specific immune response when injected into mice. To address whether Hsp72-expressing B16 cells could elicit a functional immune response in vivo, we assessed the capacity of Hsp72-expressing B16 cells to immunize mice against a subsequent challenge with wild-type B16 cells, which do not express Hsp72 constitutively. Mice immunized with control-transfected B16 cells developed wild-type challenge tumors with kinetics similar to mice treated with saline alone (mean onset of tumor ϭ 13 days) ( Fig. 7 ; open symbols). However, mice immunized with Hsp72-expressing B16 cells prior to challenge with wild-type B16 remained tumor-free throughout the course of the experiment ( Fig. 7; closed circles) . Therefore, mice immunized with Hsp72-expressing B16 cells were significantly more resistant to challenge with wild-type B16.
Discussion
The The mechanism by which Hsp72 influences the surface expression of MHC class I is unclear. However, in poorly immunogenic tumor cells such as the B16 melanoma, spontaneous down-regulation of various components of the antigen processing machinery such as TAP heterodimers or proteasome subunits (3, 5, 29, 31) results in a sharp reduction in the supply of peptides for presentation by MHC class I. Because the transit of functional MHC class I to the plasma membrane is dependent on the assembly of peptide-α chain-β 2 M complexes in the ER (30, 32, 33) , an explanation for the effect of Hsp72 could be that increased chaperone activity enhances either the amount of available MHC class I α chains or the flow of antigenic peptides into the ER. Because control cells and Hsp72-expressing cells contain a comparable steady-state level of free MHC class I α chains, we favor a scenario in which Hsp72 augments the peptide-driven assembly and trafficking of MHC class I complexes using the wild-type level of endogenous α chains. Consistent with this scenario is the detection of significant levels of peptide-bound MHC class I molecules on Hsp72-expressing (but not wildtype) cells, which is in contrast to the MHC normally detected on cells when the supply of antigenic peptides is limiting. Cells that are defective in peptide transport display primarily 'empty' MHC class I molecules on their surface (30) , even when genetically modified to express heterologous MHC class I α chains from a strong promoter (34, 35) . A role for Hsp72 in the trafficking of antigenic peptides has been suggested by Srivastava and colleagues (36, 37) , who have shown recently that exogenous peptides administered as a complex with Hsp72 are efficiently shunted into the MHC class I presentation pathway (38) .
Overexpression of Hsp72 does not restore MHC class I surface expression or endogenous antigen presentation in TAP-mutant RMA-S cells, indicating that the expression of Hsp72 affects either TAP-mediated peptide transport or an upstream step which depends on the activity of TAP for its ultimate effect. These data also suggest that Hsp72 cannot directly mediate the translocation of peptides from the cytosol into the ER. Therefore, the mechanism by which Hsp72 upregulates MHC class I surface expression is likely different 
